A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects

Phase 1 Not yet recruiting 192 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.

Timeline

Start: 2026-04-20
Primary completion: 2026-10-01
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OCANKITUG	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.